Donor Immune Cells Enter Cancer Trials as CytoMed Bets on Off-the-Shelf CAR-T Approach
Singapore’s CytoMed is engineering gamma delta T cells into a cancer cell therapy that can be supplied by donors, seeking to bypass the costly and slow manufacturing bottleneck of personalized CAR-T; but the technology has only just entered early human trials, and still has a clinical path ahead before efficacy can be proven.